Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

2017 Cancer Advances Report 2: Patient-Centered Treatments, Clinical Trials and New Drugs

2017 Cancer Advances Report 2: Patient-Centered Treatments, Clinical Trials and New Drugs

In the 21st century, cancer patients receive treatments prolonging life while gaining fuller, higher-quality lives. Research steadily improves survival across cancer types. Physical recovery is our main aim, but %100 health also requires psychological well-being. Cancer only be new treatment approaches increasingly emphasize psychosocial needs.

Technology provides easy access to health information. Patients actively contribute to decisions about illness and treatment. Imaging, precautions and treatment choices consider emotional state and values. The era of unilateral physician decisions is giving way to patient-centered care. Targeted drugs are developed considering lifestyle and environmental factors alongside genetics.

Every patient deserves the best treatment and care. Emerging web-based applications allow daily symptom recording and information access. Navigation applications provide assistance. Preventing chemotherapy nausea is another quality-of-life research focus.

Government Support for Clinical Research

Research is supported by government or private sectors. Important prevention, imaging and treatment-comparison studies attract little private support and mainly rely on government.

Research priorities reflect development and values. They accelerate progress, enable breakthroughs and save lives. Investment across science helps anticipate the future and may eventually prevent cancer and other life-shortening diseases.

government support clinical cancer research infographic JCO ASCO 2017

Table: Cancer Drugs FDA-Approved Between 1 November 2015-31 October 2016:

New Approvals

For which situations?

Approval Date

Osimertinib

Metastatic EGFR T790M-mutated NSCLC progressing during or after EGFR TKI therapy

November 2015

Daratumumab

Multiple myeloma after 3 or more prior treatment lines

November 2015

Ixazomib

Multiple myeloma after at least 1 prior line, combined with Lenalidornidin and dexamethasone

November 2015

Necitumumab

First-line metastatic squamous NSCLC, combined with gemcitabine and cisplatin

November 2015

Alectinib

Progressing metastatic ALK-positive NSCLC / crizotinib intolerance

December 2015

Venetoclax

17p-deleted CLL (chronic lymphocytic leukemia) after one or more treatments

April 2016

Cabozantinib

Advanced kidney cancer after antiangiogenic therapy

April 2016

Atezolizumab

Locally advanced or metastatic urothelial carcinoma after or during platinum chemotherapy—or given with platinum chemotherapy within 12 months of neoadjuvant–adjuvant treatment.

May 2016

Table 2: Among cancer drugs approved from November 2015-31 October 2016, those previously approved for other indications and given new uses

New Uses

For which situations?

Approval Date

Trametinib and Dabrafenib

Metastatic melanoma (skin cancer) with BRAFV600E or V600K mutation

November 2015

Nivolumab

Advanced kidney cancer after antiangiogenic therapy

November 2015

Ofatumumab

Recurrent or progressing CLL after partial or complete response to one or two treatments

January 2016

Eribulin

Metastatic liposarcoma after initial anthracycline-containing treatment

January 2016

Palbociclib

Hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, with fulvestrant after endocrine therapy

February 2016

Obinutuzumab

Follicular lymphoma, combined with bendamustine

February 2016

Everolimus

Progressing well-differentiated, nonfunctional gastrointestinal or lung neuroendocrine tumors

February 2016

Crizotinib

ROS1-positive metastatic NSCLC

March 2016

Lenvatinib

Advanced kidney cancer after antiangiogenic drugs, combined with everolimus

May 2016

Nivolumab

Recurrent classic Hodgkin lymphoma or progression after autologous hematopoietic stem cell transplantation

May 2016

EGFR mutation test v2

Detection of EGFR exon 19 deletion or exon 21 substitution mutations to establish erlotinib suitability in NSCLC

June 2016

Pembrolizumab

Recurrent or metastatic squamous head-and-neck cancer after platinum chemotherapy or progression during it

August 2016

Atezolizumab

Metastatic NSCLC progressing after or during platinum chemotherapy

October 2016

Sources

Harold J. Burstein, Lada Krilov, Jeanny B. Aragon-Ching et. al.,
Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.
J Clin Oncol 35. 2017 by American Society of Clinical Oncology

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

2017 Cancer Advances Report 2: Patient-Centered Treatments, Clinical Trials and New Drugs

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy